Merigolix

Merigolix (INNTooltip International Nonproprietary Name; developmental code names HS-10518, NCE-403, SKI-2670, TU-2670) is a gonadotropin releasing hormone (GnRH) antagonist which is under development for the treatment of endometriosis and uterine fibroids.^{[1][2][3][4][5]} It is taken by mouth.^[1] The drug is being developed by TiumBio, Daewon Pharmaceutical, and Jiangsu Hansoh Pharmaceutical.^[1][2] As of October 2024, it is in phase 2 clinical trials for both endometriosis and uterine fibroids.^[1][2]

Merigolix

Clinical data
Other names	HS-10518; NCE-403; SKI-2670; TU-2670
Routes of administration	Oral[1]
Drug class	GnRH antagonist
Identifiers
IUPAC name 4-[[(1R)-2-[1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-2,4-dioxo-1'-[[5-(trifluoromethyl)furan-2-yl]methyl]spiro[7H-furo[3,4-d]pyrimidine-5,4'-piperidine]-3-yl]-1-phenylethyl]amino]butanoic acid
CAS Number	1454272-94-6
PubChem CID	71727383
ChemSpider	128922028
UNII	RS62JYV9LX
ChEMBL	ChEMBL5314469
Chemical and physical data
Formula	C36H35F7N4O6
Molar mass	752.687 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CCC12C3=C(CO2)N(C(=O)N(C3=O)C[C@@H](C4=CC=CC=C4)NCCCC(=O)O)CC5=C(C=CC=C5F)C(F)(F)F)CC6=CC=C(O6)C(F)(F)F
InChI InChI=1S/C36H35F7N4O6/c37-26-9-4-8-25(35(38,39)40)24(26)19-46-28-21-52-34(13-16-45(17-14-34)18-23-11-12-29(53-23)36(41,42)43)31(28)32(50)47(33(46)51)20-27(22-6-2-1-3-7-22)44-15-5-10-30(48)49/h1-4,6-9,11-12,27,44H,5,10,13-21H2,(H,48,49)/t27-/m0/s1 Key:LJPSGSMPGVITHK-MHZLTWQESA-N

See also

• List of investigational sex-hormonal agents